Canton Strategic Holdings Inc. (CNTN) carries a Roarable Rating of D- (Sell) with 37/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Canton Strategic Holdings Inc. (NASDAQ: CNTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.95 (-4.88% 1D, market cap $163.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNTN ranks #613 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -4.1%. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and PEPG (PepGen Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $166.9M). Among the 5-stock peer group, CNTN leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
Per CNTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861657), Canton Strategic Holdings Inc. generated $0 in revenue, -$35.9M in net income, and -$16.1M in free cash flow against $519.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While CNTN currently carries a cautious 37/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.15) and Max Pain ($2.05) forces dealer call-delta covering toward $7.23.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Canton Strategic Holdings Inc. (CNTN) dropped -4.88% to $1.95, trading at 6% of its 52-week range ($1.66 – $6.89). Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.
unchainedcrypto.com report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
24/7 Wall St. report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
CoinDesk report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Canton Strategic Holdings (NASDAQ: $CNTN) plans to let its common shares trade in tokenized form on the Canton Netw...
Announcement Follows SEC's Innovation Exemption, Paving the Way for Compliant Onshore Access, 24/7 Trading, and Atomic Settlement of Tokenized EquitiesTokenized Shares Issued by Onchain Transfer Agent Fairmint and
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CNTN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CNTN. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Canton Strategic Holdings Inc. (CNTN) ranks #613 by composite RQD confidence (37/100, grade D-) and #601 by equity capitalization ($163.3M). Within this direct 5-issuer industry benchmark cohort, CNTN leads on earnings valuation at N/A trailing P/E, while CNTN leads on capital efficiency and profitability with -4.1% ROIC and — gross margin. VRXA currently holds the highest overall quantitative score in the immediate peer group at 60/100 (C-) compared with CNTN at 37/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CNTN
ACTIVE
Canton Strategic Holdings Inc. | D- | 37/100 | — | — | -4.1% | -4.88% | $163.3M | Benchmark Subject |
| PDSB PDS Biotechnology Corporation | D | 45/100 | — | — | -35.0% | -7.10% | $162.8M | /pdsb-vs-cntn → |
| PEPG PepGen Inc. | D- | 38/100 | — | — | -35.0% | -2.08% | $166.9M | /pepg-vs-cntn → |
| VRXA Veraxa Biotech AG | C- | 60/100 | — | — | — | +0.89% | $159.8M | /vrxa-vs-cntn → |
| CUE Cue Biopharma Inc. | E | 33/100 | — | — | -35.0% | -2.70% | $155.8M | /cue-vs-cntn → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Canton Strategic Holdings Inc. (CNTN) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$35.9M, operating cash flow of -$16.1M, and free cash flow of -$16.1M (-47.9% YoY). On the balance sheet, CNTN closed FY2025 with $519.1M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$35.9M | -$16.1M | -$16.1M | $519.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$12.2M | -$10.9M | -$10.9M | $3.7M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$9.3M | -$7.3M | -$7.3M | — | — |
As of 2026-11-02, Canton Strategic Holdings Inc. (NASDAQ: CNTN) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 37/100 at a spot price of $1.95 (-4.88% 1D, market cap $163.3M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CNTN ranks #613 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CNTN carries a Roarable D- (37/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -4.1%. By comparison, PDSB (PDS Biotechnology Corporation) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $162.8M) and PEPG (PepGen Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $166.9M). Among the 5-stock peer group, CNTN leads on earnings multiple (N/A) while CNTN leads on capital efficiency (-4.1% ROIC).
Per CNTN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001861657), Canton Strategic Holdings Inc. generated $0 in revenue, -$35.9M in net income, and -$16.1M in free cash flow against $519.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
CNTN last traded at $1.95 (-4.88% on volume of 533,031 shares), positioning the stock -9.30% below its 50-day simple moving average ($2.15) and -34.34% below its 200-day simple moving average ($2.97). Across its 52-week range of $1.66 to $6.89, CNTN sits at the 5.5% percentile with a 14-day RSI of 46.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.71 to $2.19).
Why CNTN Stock dropped -4.88% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-4% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD rating, CNTN scores 37 out of 100, earning a D- grade and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars: Fundamental Cash Engine scores 8/20 (ROIC of -4.1% and FCF yield of -9.87%), indicating the business is not currently generating returns on invested capital or free cash flow. Whale 13F Flow scores 8/20 for institutional accumulation and options positioning, a modest signal. Insider Conviction scores 3/20 on SEC Form 4 and Congressional PTR cluster flow, the weakest pillar and a signal of limited insider confidence. Macro Regime Fit scores 8/20 with a beta of 1.0, meaning market-level moves are expected to be mirrored one-for-one. Forensic Balance Sheet scores 10/20, reflecting an Altman Z of 2.5, a Piotroski F of 2/9, and a debt-to-equity ratio of 0.5.
For a prospective investor evaluating the stock today, the upside case rests on the tokenization news flow and any future reversal in cash generation, but the source data shows no current cash engine, weak insider flow, and a weak Piotroski reading. Valuation cannot be assessed on earnings because P/E and EV/EBITDA are not available in source data, and the negative free cash flow yield means traditional cash-based valuation support is absent.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-20.1M | $-35.9M | N/A | $-16.1M | $12.0M | N/A |
| FY 2024 | $0.0M | $-12.4M | $-12.2M | N/A | $-10.9M | $3.6M | N/A |
| FY 2023 | $0.0M | $-9.5M | $-9.3M | N/A | $-7.3M | N/A | N/A |
Per the SEC financials, the company reported no revenue and losses widened each year, with FY 2025 net income at $-35.9M against FY 2024 at $-12.2M. Gross, operating, and net margins are each 0% per the market data, and ROIC is -4.1%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9 per the Roarable RQD rating. Debt-to-equity is 0.5; cash rose from $3.6M at FY 2024 to $12.0M at FY 2025, but the source data does not provide a debt figure to assess the balance sheet further.
The news wire is dominated by a single theme: a tokenization initiative in which CNTN is described as moving to tokenize its own shares under a new SEC exemption and aiming for a first-trade debut on Canton. Headlines are tagged YELLOW (MARKET WIRE) except one GREEN CATALYST item, a CoinDesk report stating a tokenized stock venue on Canton could beat OKX–ICE to a first trade under the SEC framework. One item notes that more than 30 firms took part in a pilot covering digital stock transfers and Treasury deals. A BigGo Finance item references a Nov. 2 debut. Risk watch: the catalyst narrative is not paired with reported revenue in the source data. Proprietary signals: none, per the Butterfly Supply-Chain Graph.
Real-time company headlines, analyst actions, and sector developments for Canton Strategic Holdings Inc. (CNTN) • Click "Debate This Headline" to argue it in the Roar Pit below
unchainedcrypto.com report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
24/7 Wall St. report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
TradingView report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
BigGo Finance report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
CoinDesk report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Kalkine Media report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Canton Strategic Holdings Inc. (CNTN) market action, institutional positioning, and fundamental catalysts.
Welcome to the CNTN (Canton Strategic Holdings Inc.) Roar Pit. Current RQD Composite is 37/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on CNTN, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Canton Strategic Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on CNTN, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.95 (52-wk range $1.66 - $6.89), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).